Abstract: The invention relates to a composition which is effective as a flotation reagent for collecting and separating potash salt mixtures. The flotation reagent comprises A) at least one compound of the formula [R1—NH3]+X?, where R1 is a C8 to C22 alkyl radical and X? is an anion, and B) a branched fatty acid having a chain length of 8 to 22 carbon atoms.

Abstract: Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula I. These compounds are found to possess the property of selectively inhibiting collagenase (MMP). They may therefore be useful in prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13.

Abstract: The invention relates to a pyrimidine-4,6-dicarboxylic acid diamide compound, pharmaceutical preparation comprising it, process for preparing it and method for its pharmaceutical use. Particularly, the pyrimidine-4,6-dicarboxylic acid diamide compound is useful for selectively inhibiting collagenase matrix metalloproteinase (MMP) 13, or for treating a degenerative joint disease.

Abstract: In order to provide a variable folder which allows smearing-free operation, the cutting blade of an upstream cross-cutting arrangement is provided with recesses, which leave behind residual crosspieces in the strand which is to be cut, and arranged in the product-directing region, between the cross-cutting arrangement and a collecting cylinder, are accelerating and tearing-off cams which grip the incoming product and tear it off from the strand at the residual crosspieces.

Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.

Abstract: Pyrimidine-4,6-dicarboxylic acid diamides of the formula I 1

Abstract: A box-erecting apparatus has a supply holding a stack of flattened blanks, an erecting station spaced in a transport direction from the supply and provided with a plunger and elements for erecting a flattened blank into an upwardly open box, and a support between the supply and the station positioned to receive a flattened blank. An inner arm between the supply and the station has an inner end pivoted about an inner axis transverse to the direction and an outer end, and an outer arm has an inner end pivoted on the inner-arm outer end about an outer axis generally parallel to the inner axis and an outer end carrying a grab. A drive can pivot the arms independently of each other about the respective axes between a position with the grab engaging one of the blanks in the support and a position depositing one of the blanks on the support.

Abstract: For the operation of contact-less identification media RF-IM in a system with contact applications C-App for contact cards C-IM, an initialised converter module C-RF is connected in series as a read/write station. This converter module, on the one hand, executes a contact-less communication K-RF with initialised contact-less identification media RF-IM and, on the other hand, a contact communication K-C at a contact card interface S to a host computer H or to an application computer App-uP for the communication with a contact application C-App of the system and the converter module translates the contact-less communication K-RF with respect to communication rules and information I-RF into a contact communication K-C with contact information I-C and vice versa. This makes possible a particularly simple and efficient introduction of contact-less identification media RF-IM into existing contact card systems and—installations.

Abstract: The invention relates to a method for detecting inhibitors or ligands of binding domains, which comprises using a protein which contains at least one catalytic domain and at least one binding domain, incubating said protein with a marker substrate which binds to the catalytic domain of the protein and is converted, with a substrate which can reversibly bind to the catalytic domain and to the binding domain, and with the inhibitor and determining whether the marker substrate is converted by the protein.

Abstract: The invention is related to compounds of formula I to pharmaceutical compositions comprising such compounds, to processes for the preparation of such compounds, and to methods of prevention and treatment of disorders, the progression of which involve an enhanced activity of matrix metalloproteinase 13, by administering to a patient in need thereof, a pharmaceutically effective amount of such compounds.

Abstract: The invention relates to a flotation agent for phosphate ore, comprising a fatty acid as collector and alkoxylated alkylphenols as dispersing agents, characterized in that the alkylphenols are composed of a) 8 to 20% by weight of one or more dialkylphenols having alkyl radicals from 8 to 12 carbon atoms b) 80 to 92% by weight of one or more monoalkylphenols having alkyl radicals from 8 to 12 carbon atoms, which have been alkoxylated with 2 to 6 mol of ethylene oxide.

Abstract: Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula I. These compounds are found to possess the property of selectively inhibiting collagenase (MMP). They may therefore be useful in prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13.

Abstract: The invention is related to compounds of formula I 1

Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids

Abstract: Agent for dressing phosphate ores

Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.

Abstract: A variable-circumference folder includes a gathering cylinder fitted with pin systems for reliably holding products of different thickness fed to the gathering cylinder by an accelerating device without any adjustment effort.

Abstract: With the method, mobile data carriers (IM) are initialised at assigned decentralised read and write stations (WR) within the framework of an authorisation system (A). At an authorisation authority (HA) in a secure environment (g) initialisation data (DI, A-I, I-I) are generated by authorisation means (AM) and transmitted to a decentralised authorised read and write station (A-WR) through a network (N) in a secure communication and with security rules in correspondence with the authorisation system (A), where the mobile data carriers (IM) are initialised with the initialisation data (DI), and/or wherein the initialisation data are transmitted to a decentralised read and write station (WR) through the network, by means of which the read and write station is initialised. This initialisation method makes possible new possibilities for the application and exploitation of systems of this kind.

Abstract: Compounds of the formula (I): are suitable for the preparation of pharmaceuticals for prophylaxis and treatment of all those diseases where an increased concentration of interleukin-1&bgr; participates in their course, for example septic shock, leukemia, hepatitis, muscular degeneration, HIV infections or degenerative joint diseases (such as osteoarthrosis, spondylosis, chondrolysis following joint trauma or prolonged immobilization of joints following meniscus or patella injuries, or torn ligaments), diseases of the connective tissue (such as collagenosis, periodontal diseases, or wound-healing disturbances), and chronic diseases of the locomotor system (such as inflammatory or immunologically or metabolism-related acute and chronic arthritis, arthropathies, rheumatoid arthritis, myalgias and disturbances in bone metabolism).

Abstract: Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved.